CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Schultz LM, Jeyakumar N, Kramer AM, Sahaf B, et al. Leukemia 2024;38:963-968.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Schultz LM, Jeyakumar N, Kramer AM, Sahaf B, et al. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Leukemia 2024;38:963-968.
PMID: 38491306